Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
by Richard Daverman, PhD
June 3, 2013 -- Genor Biopharma of Shanghai has agreed with BioCND, a Korean biosimilar CRO and consulting firm, to co-develop biosimilars of two popular monoclonal antibodies: Humira, an arthritis treatment, and Herceptin, a cancer drug. BioCND will have marketing rights to the products in emerging countries, but not China. Genor was responsible for the original development of the two molecules. More details....
Help employers find you! Check out all the jobs and post your resume.
by Richard Daverman, PhD
June 3, 2013 -- Genor Biopharma of Shanghai has agreed with BioCND, a Korean biosimilar CRO and consulting firm, to co-develop biosimilars of two popular monoclonal antibodies: Humira, an arthritis treatment, and Herceptin, a cancer drug. BioCND will have marketing rights to the products in emerging countries, but not China. Genor was responsible for the original development of the two molecules. More details....
Help employers find you! Check out all the jobs and post your resume.
